Table 1.
Hospitalization rates
| Children ≤ 2 years old with BPD/CLD (n = 3675) | Infants at gestational age 29–32 weeks without CLD (n = 4854) | Infants at gestational age 32–35 weeks without CLD (n = 2829) | ||||
| Reference (country) | Untreated | Palivizumab | Untreated | Palivizumab | Untreated | Palivizumab |
| [23] (USA) | 36.7% (30) | - | - | - | - | - |
| [24] (USA) | 17.4% (149) | - | - | - | - | - |
| [52] (USA) | 25.2% (131) | - | 7.6% (662) | - | - | - |
| [53] (UK) | 19.1% (235) | - | - | - | - | - |
| [32] (USA/Can/UK) | 12.8% (266) | 7.9% (496) | 8.5% (142) | 1.6% (313) | 9.8% (123) | 2.0% (250) |
| [35] (USA; outcomes 1998–1999) | - | 4.0% (402) | - | 2.0% (506) | - | 1.5% (548) |
| [36] (USA; outcomes 1999–2000) | - | 3.9% (795) | - | 2.3% (690) | - | 1.3% (972) |
| [39] (Canada) | - | 6.0% (95) | - | 1.3% (199) | - | - |
| [40] (The Netherlands) | - | 3.4% (88) | - | 0.8% (124) | - | - |
| Unpublished data (France) | - | 7.6% (506) | - | - | - | - |
| [37] (USA; registry 2000–2001) | - | 5.8% (482) | - | 2.3% (650) | - | 1.6% (936) |
| [54] (Spain) | - | - | 10.1% (456) | - | - | - |
| [55] (Spain) | - | - | 12.9% (827) | - | - | - |
| [41] (international study) | - | - | - | 2.1% (285) | - | - |
| Weighted mean rate | 18.4% (811) | 5.6% (2864) | 10.3% (2087) | 2.0% (2767) | 9.8% (123) | 1.5% (2706) |
Values are expressed as % (n). Hospitalization rates due to respiratory syncytial virus (RSV) in children ≤ 2 years old with bronchopulmonary dysplasia (BPD)/chronic lung disease (CLD), infants at gestational age 29–32 weeks without CLD, and infants at gestational age 32–35 weeks without CLD (combined analysis). -, not studied. Adapted from Simoes [44].